Pulmonary Hypertension Drugs Market is driven by Rising Disease Prevalence
Pulmonary hypertension drugs encompass a diverse portfolio of therapeutic agents designed to lower pulmonary arterial pressure, improve right ventricular function and enhance patient quality of life. Key classes include endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE-5) inhibitors, prostacyclin analogs and soluble guanylate cyclase (sGC) stimulators. These products offer...
0 Commentaires 0 Parts 83 Vue 0 Aperçu